Literature DB >> 17110288

The HTLV-1 neurological complex.

Abelardo Q C Araujo1, Marcus Tulius T Silva.   

Abstract

Human T-cell lymphotropic virus type 1 (HTLV-1) is a retrovirus that infects about 20 million people worldwide and causes immune-mediated diseases of the nervous system. The classic neurological presentation of HTLV-1 infection is a myelopathy called HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). However, HAM/TSP is not the only neurological outcome that can result from HTLV-1 infection. In this Personal View, we show that HTLV-1 has a broader neurological spectrum than the names HAM/TSP suggest and that people infected with this virus can present with various isolated or assorted syndromes.

Entities:  

Mesh:

Year:  2006        PMID: 17110288     DOI: 10.1016/S1474-4422(06)70628-7

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  61 in total

1.  Human T-lymphotropic virus type I or II (HTLV-I/II) associated with recurrent longitudinally extensive transverse myelitis (LETM): two case reports.

Authors:  Silvia R Delgado; William A Sheremata; Andrew D Brown; Micheline McCarthy
Journal:  J Neurovirol       Date:  2010-05       Impact factor: 2.643

2.  Effects of Physiotherapy in the Treatment of Neurogenic Bladder in Patients Infected With Human T-Lymphotropic Virus 1.

Authors:  Rosana C P Andrade; José A Neto; Luciana Andrade; Tatiane S Oliveira; Dislene N Santos; Cassius J V Oliveira; Márcio J Prado; Edgar M Carvalho
Journal:  Urology       Date:  2015-12-24       Impact factor: 2.649

3.  Sensory neuronopathy heralding human T cell lymphotropic virus type I myelopathy.

Authors:  Alberto R M Martinez; Raphael F Casseb; Carlos R Martins; Anamarli Nucci; Marcondes C França
Journal:  J Neurovirol       Date:  2018-01-09       Impact factor: 2.643

4.  Peripheral nervous system manifestations of infectious diseases.

Authors:  Kate T Brizzi; Jennifer L Lyons
Journal:  Neurohospitalist       Date:  2014-10

5.  Subacute progression of human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis.

Authors:  Marco A Lima; Ramza C Harab; Doris Schor; Maria J Andrada-Serpa; Abelardo Q C Araújo
Journal:  J Neurovirol       Date:  2007-10       Impact factor: 2.643

6.  Genes related to antiviral activity, cell migration, and lysis are differentially expressed in CD4(+) T cells in human t cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis patients.

Authors:  Mariana Tomazini Pinto; Tathiane Maistro Malta; Evandra Strazza Rodrigues; Daniel Guariz Pinheiro; Rodrigo Alexandre Panepucci; Kelen Cristina Ribeiro Malmegrim de Farias; Alessandra De Paula Sousa; Osvaldo Massaiti Takayanagui; Yuetsu Tanaka; Dimas Tadeu Covas; Simone Kashima
Journal:  AIDS Res Hum Retroviruses       Date:  2013-10-16       Impact factor: 2.205

7.  SHP-1 deficiency and increased inflammatory gene expression in PBMCs of multiple sclerosis patients.

Authors:  George P Christophi; Chad A Hudson; Ross C Gruber; Christoforos P Christophi; Cornelia Mihai; Luis J Mejico; Burk Jubelt; Paul T Massa
Journal:  Lab Invest       Date:  2008-01-21       Impact factor: 5.662

8.  Common γ-chain blocking peptide reduces in vitro immune activation markers in HTLV-1-associated myelopathy/tropical spastic paraparesis.

Authors:  Raya Massoud; Yoshimi Enose-Akahata; Yutaka Tagaya; Nazli Azimi; Asjad Basheer; Steven Jacobson
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-17       Impact factor: 11.205

9.  Early neurologic abnormalities associated with human T-cell lymphotropic virus type 1 infection in a cohort of Peruvian children.

Authors:  Emily A Kendall; Elsa González; Iván Espinoza; Martín Tipismana; Kristien Verdonck; Daniel Clark; Sten H Vermund; Eduardo Gotuzzo
Journal:  J Pediatr       Date:  2009-07-22       Impact factor: 4.406

10.  Macrophages of multiple sclerosis patients display deficient SHP-1 expression and enhanced inflammatory phenotype.

Authors:  George P Christophi; Michael Panos; Chad A Hudson; Rebecca L Christophi; Ross C Gruber; Akos T Mersich; Scott D Blystone; Burk Jubelt; Paul T Massa
Journal:  Lab Invest       Date:  2009-04-27       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.